To support the validation and verification of new assays and to challenge the existing assays in oncology testing, Thermo Fisher Scientific launches Thermo Scientific Acrometrix BCR-ABL Panel. The ...

Thirteen patients were treated during study (Table 1). Vaccination was generally well tolerated with the most common toxicity being local induration or erythema at the site of inoculation. Eleven ...

Calculating halving time of the BCR-ABL transcript after 3 months may help determine prognosis in chronic myeloid leukaemia (CML) patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy ...

Expression of CD74 by AML blasts and cell lines, and enhanced in vitro cytotoxicity of anti-CD74 antibody after interferon-gamma (IFN-γ) treatment. Background: Current NCCN guidelines recommend ...

Progressing Phase 1/2 clinical trial of THE-630 in advanced GIST; preliminary dose-escalation data anticipated in Q2 2023 with additional data expected in Q4 2023 IND submission for 4G EGFR inhibitor ...

Terns Pharmaceuticals Inc., a NASH specialist based in San Francisco and Shanghai, has out-licensed the Greater China rights of its BCR-ABL inhibitor, TRN-000632, for treating chronic myeloid leukemia ...

SUZHOU, China and ROCKVILLE, Md., March 24, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, ...

A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". SUZHOU, China and ROCKVILLE, Md., Oct. 21, 2020 /PRNewswire/ -- Ascentage ...